← Back to all trials
Enrolling By Invitation
NCT05709171
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
Conditions: GEP-NET, Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Carcinoma Metastatic
Sex: All
Ages: 18 Years – N/A
Phase: PHASE2
Enrollment: 200
Sponsor: Rigshospitalet, Denmark
Location: Denmark
Summary
Prospective clinical trial investigating combined, dual 18F-FDG PET/CT and 64Cu-DOTATATE PET/CT imaging of patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN)
Eligibility Criteria
Inclusion Criteria:Histopathologically verified gastro-entero-pancreatic neuroendocrine neoplasm (GEP-NEN) or patients with unknown primary tumor with metastases with verified NEN positive histopathological examination suggesting GEP originWorld Health Organization (WHO) Performance status 0-2Must be able to read and understand the patient information in Danish and to give informed consentExclusion Criteria:PregnancyBreast-feedingWeights more than the maximum weight limit for the PET/CT bed of the scanner (140 kg)Uncontrolled diabetesUncontrolled infectionExacerbation in autoimmune diseasesOther active cancer diseaseConditions or diseases (e.g.
uncontrolled Parkinson's disease) making the patient unable to lie still in the scannerSevere claustrophobiaLocalized neuroendocrine neoplasms of the appendix, the rectum measuring < 1 cm, and ECL-omas of the stomachHistory of allergic reaction attributable to compounds of similar chemical or biologic com-position to 18FDG or 64Cu-DOTATATE
Source: ClinicalTrials.gov (NCT05709171). StuddyBuddy aggregates publicly available trial information.
